Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga ...

Fibryga (R) is now approved in the U.S. for fibrinogen supplementation in both congenital and acquired fibrinogen deficiency, and is available in 1-gram and 2-gram kits, each with the nextaro (R) ...

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

What Is Fesilty, and Why Does It Matter? Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital ...

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard ...

PARAMUS, N.J, Aug. 1, 2024 /PRNewswire/ -- Octapharma USA, Inc. has announced the expanded approval of fibryga ®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for fibrinogen replacement ...

Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated Hemorrhagic Shock Patients Cerus Corporation (Nasdaq: CERS) announced ...

Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation ...